EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study

Vivian Y Tat, Pinghan Huang, Kamil Khanipov iD, Nathan Y Tat iD, Chien-Te Kent Tseng, George Golovko

Pathogens · 2024

DOI: 10.3390/pathogens13070539 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pathogens, 2024. Verfasst von Vivian Y Tat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555, USA. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, SARS-CoV-2, COVID-19, Hospitalization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCATS NIH HHS, Institute for Translational Sciences at The University of Texas Medical Branch.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19) continues to cause morbidity and mortality worldwide; therefore, effective treatments remain crucial to controlling it. As interferon-alpha (IFN-α) and -beta (β) have been proposed as COVID-19 treatments, we sought to assess their effectiveness on respiratory, cardiovascular, neurological, and psychiatric signs and symptoms, as well as PASC and death, in hospitalized COVID-19 patients without multiple sclerosis (MS). Using a federated data research network (TriNetX), we performed a retrospective cohort study of hospitalized COVID-19 patients without MS who received IFN-α or -β treatment, comparing them to a similar cohort who did not receive treatment. Following propensity-score matched analyses, we demonstrate that hospitalized COVID-19 patients who were treated with IFN-α or -β had significantly higher odds of death. In contrast, there was no significant difference in any other outcomes between 1–30 days or 1 day to anytime afterward. Overall, hospitalized COVID-19 patients without MS who were treated with IFN-α or -β had similar short- and long-term sequelae (except for mortality) as those who did not receive treatment. The potential benefits of utilizing IFN-α or -β treatment as therapeutics remain to be realized, and our research highlights the need to explore repurposing drugs for COVID-19 using real-world evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentSARS-CoV-2COVID-19HospitalizationAntiviral AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedAdultInterferon Type IInterferon-alphaInterferon-betaTreatment Outcome

Stichwörter der Autor:innen

COVID-19interferonssequelaetreatments

Substanzen

Antiviral AgentsInterferon Type IInterferon-alphaInterferon-beta

Autor:innen und Institutionen

  • Department of Pathology, The University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Department of Microbiology & Immunology, The University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Department of Pharmacology & Toxicology, The University of Texas Medical Branch, Galveston, TX 77555, USA.
  • Taking Our Best Shot, Galveston, TX 77555, USA.

ORCID-Profile: Kamil Khanipov, Nathan Y Tat

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • Institute for Translational Sciences at The University of Texas Medical Branch
  • Clinical and Translational Science Award
  • West African Center for Emerging Infectious Diseases

Zitieren

APA

Tat, V. Y., Huang, P., Khanipov, K., Tat, N. Y., Tseng, C. K., & Golovko, G. (2024). Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. Pathogens. https://doi.org/10.3390/pathogens13070539

Vancouver

Tat VY, Huang P, Khanipov K, Tat NY, Tseng CK, Golovko G. Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. Pathogens. 2024. doi:10.3390/pathogens13070539

BibTeX
@article{Tat2024,
  author = {Tat, Vivian Y and Huang, Pinghan and Khanipov, Kamil and Tat, Nathan Y and Tseng, Chien-Te Kent and Golovko, George},
  title = {Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study},
  journal = {Pathogens},
  year = {2024},
  doi = {10.3390/pathogens13070539}
}
Kostenlos starten →